Who
Matthew Bowen
Principal Accounting Officer
Company insider
Files Form 4 as: Principal Accounting Officer, Monte Rosa Therapeutics.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $137
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Apr 2026
- Last trade
- 5 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 6 Oct 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Sold | $13713 at $10.56 | filing |
| 6 Apr 2026filed 7 Apr 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,300 | filing |
| 6 Apr 2026filed 7 Apr 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 6 Apr 2026filed 7 Apr 2026 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,500 at $0.00 | filing |
| 6 Apr 2026filed 7 Apr 2026 | GLUE Monte Rosa TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,300 | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)GLUE · tickerreport.com · 16 Oct 2026Monte Rosa Therapeutics (NASDAQ:GLUE) Upgraded to "Hold" at UBS GroupGLUE · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Matthew Bowen; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.